- Email: [email protected]
Correction to Lancet Oncol 2015; 16: 522
Corrections
Correction to Lancet Oncol 2015; 16: 522
Correction to Lancet Oncol 2016; 17: 553
Correction to Lancet Oncol 2016; 17: 733
Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–30—In this Article, the affiliation for Virginia Ferraresi was incorrect. This correction has been made to the online version as of June 1, 2016.
Philip, PA. Targeting macrophages to treat pancreatic cancer. Lancet Oncol 2016; 17: 552–53—In this Comment, reference 6 was accidentally not numbered, and was included after reference 2. This correction has been made to the online version as of June 1, 2016.
Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In this Article, data for the adjusted time to local progression were reported twice. The seventh sentence of the seventh paragraph of the Results has been removed. This correction has been made to the online version as of June 1, 2016, and the printed version is correct.
Correction to Lancet Oncol 2016; 17: 751 Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016; 17: 747–56— In table 1 of this Article, the row heading “Seminal vesicle involvement” should have been “No seminal vesicle involvement”. This correction has been made to the online version as of June 1, 2016, and the printed version is correct.
www.thelancet.com/oncology Vol 17 June 2016
e223
Correction to Lancet Oncol 2015; 16: 522
Correction to Lancet Oncol 2016; 17: 553
Correction to Lancet Oncol 2016; 17: 733
Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–30—In this Article, the affiliation for Virginia Ferraresi was incorrect. This correction has been made to the online version as of June 1, 2016.
Philip, PA. Targeting macrophages to treat pancreatic cancer. Lancet Oncol 2016; 17: 552–53—In this Comment, reference 6 was accidentally not numbered, and was included after reference 2. This correction has been made to the online version as of June 1, 2016.
Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In this Article, data for the adjusted time to local progression were reported twice. The seventh sentence of the seventh paragraph of the Results has been removed. This correction has been made to the online version as of June 1, 2016, and the printed version is correct.
Correction to Lancet Oncol 2016; 17: 751 Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016; 17: 747–56— In table 1 of this Article, the row heading “Seminal vesicle involvement” should have been “No seminal vesicle involvement”. This correction has been made to the online version as of June 1, 2016, and the printed version is correct.
www.thelancet.com/oncology Vol 17 June 2016
e223